148 related articles for article (PubMed ID: 33941395)
21. Rare form of cherubism: Case report with review of literature.
Mani S; Natarajan B; Rajaram K; Sahuthullah YA; Gokulanathan S; Sitra G
J Pharm Bioallied Sci; 2013 Jul; 5(Suppl 2):S142-6. PubMed ID: 23956593
[TBL] [Abstract][Full Text] [Related]
22. Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model.
Yoshimoto T; Hayashi T; Kondo T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2018 Aug; 33(8):1513-1519. PubMed ID: 29669173
[TBL] [Abstract][Full Text] [Related]
23. SH3BP2 mutations potentiate osteoclastogenesis via PLCγ.
Lietman SA; Yin L; Levine MA
J Orthop Res; 2010 Nov; 28(11):1425-30. PubMed ID: 20872577
[TBL] [Abstract][Full Text] [Related]
24. Cherubism. A case report.
Cariati P; Monsalve Iglesias F; Fernández Solís J; Valencia Laseca A; Martinez Lara I
Reumatol Clin; 2017; 13(6):352-353. PubMed ID: 27427211
[TBL] [Abstract][Full Text] [Related]
25. Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss.
Yoshitaka T; Ishida S; Mukai T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2014; 29(5):1170-82. PubMed ID: 24978678
[TBL] [Abstract][Full Text] [Related]
26. Characterization of a Norwegian cherubism cohort; molecular genetic findings, oral manifestations and quality of life.
Prescott T; Redfors M; Rustad CF; Eiklid KL; Geirdal AØ; Storhaug K; Jensen JL
Eur J Med Genet; 2013 Mar; 56(3):131-7. PubMed ID: 23298620
[TBL] [Abstract][Full Text] [Related]
27. Craniofacial and Dental Features in Six Children With Cherubism.
Stoor P; Suomalainen A; Kemola W; Arte S
J Craniofac Surg; 2017 Oct; 28(7):1806-1811. PubMed ID: 28857986
[TBL] [Abstract][Full Text] [Related]
28. NFATc1 and TNFalpha expression in giant cell lesions of the jaws.
Amaral FR; Brito JA; Perdigão PF; Carvalho VM; de Souza PE; Gomez MV; De Marco L; Gomez RS
J Oral Pathol Med; 2010 Mar; 39(3):269-74. PubMed ID: 20002873
[TBL] [Abstract][Full Text] [Related]
29. Pro416Arg cherubism mutation in Sh3bp2 knock-in mice affects osteoblasts and alters bone mineral and matrix properties.
Wang CJ; Chen IP; Koczon-Jaremko B; Boskey AL; Ueki Y; Kuhn L; Reichenberger EJ
Bone; 2010 May; 46(5):1306-15. PubMed ID: 20117257
[TBL] [Abstract][Full Text] [Related]
30. A c.1244G>A (p.Arg415Gln) mutation in SH3BP2 gene causes cherubism in a Turkish family: report of a family with review of the literature.
Sekerci AE; Balta B; Dundar M; Hu Y; Reichenberger EJ; Etoz OA; Nazlim S; Bayrakdar IS
Med Oral Patol Oral Cir Bucal; 2014 Jul; 19(4):e340-4. PubMed ID: 24608212
[TBL] [Abstract][Full Text] [Related]
31. Cherubism as a systemic skeletal disease: evidence from an aggressive case.
Morice A; Joly A; Ricquebourg M; Maruani G; Durand E; Galmiche L; Amiel J; Vial Y; Cavé H; Belhous K; Piketty M; Cohen-Solal M; Berdal A; Collet C; Picard A; Coudert AE; Kadlub N
BMC Musculoskelet Disord; 2020 Aug; 21(1):564. PubMed ID: 32825821
[TBL] [Abstract][Full Text] [Related]
32. Enhanced TLR-MYD88 signaling stimulates autoinflammation in SH3BP2 cherubism mice and defines the etiology of cherubism.
Yoshitaka T; Mukai T; Kittaka M; Alford LM; Masrani S; Ishida S; Yamaguchi K; Yamada M; Mizuno N; Olsen BR; Reichenberger EJ; Ueki Y
Cell Rep; 2014 Sep; 8(6):1752-1766. PubMed ID: 25220465
[TBL] [Abstract][Full Text] [Related]
33. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice.
Ueki Y; Lin CY; Senoo M; Ebihara T; Agata N; Onji M; Saheki Y; Kawai T; Mukherjee PM; Reichenberger E; Olsen BR
Cell; 2007 Jan; 128(1):71-83. PubMed ID: 17218256
[TBL] [Abstract][Full Text] [Related]
34. Novel mutation in the gene encoding c-Abl-binding protein SH3BP2 causes cherubism.
Lo B; Faiyaz-Ul-Haque M; Kennedy S; Aviv R; Tsui LC; Teebi AS
Am J Med Genet A; 2003 Aug; 121A(1):37-40. PubMed ID: 12900899
[TBL] [Abstract][Full Text] [Related]
35. A novel mutation in the SH3BP2 gene causes cherubism: case report.
Li CY; Yu SF
BMC Med Genet; 2006 Dec; 7():84. PubMed ID: 17147794
[TBL] [Abstract][Full Text] [Related]
36. Identification of a novel mutation of SH3BP2 in cherubism and demonstration that SH3BP2 mutations lead to increased NFAT activation.
Lietman SA; Kalinchinko N; Deng X; Kohanski R; Levine MA
Hum Mutat; 2006 Jul; 27(7):717-8. PubMed ID: 16786512
[TBL] [Abstract][Full Text] [Related]
37. Cherubism With Bilateral Mandible and Maxilla Involvement: A Case Report.
Yu Z; Zhai M; Gan W; Zhang H; Zhou Y; Wen H
Medicine (Baltimore); 2015 Dec; 94(49):e2120. PubMed ID: 26656340
[TBL] [Abstract][Full Text] [Related]
38. A novel mutation of the SH3BP2 gene in an aggressive case of cherubism.
Carvalho VM; Perdigão PF; Pimenta FJ; de Souza PE; Gomez RS; De Marco L
Oral Oncol; 2008 Feb; 44(2):153-5. PubMed ID: 17368082
[TBL] [Abstract][Full Text] [Related]
39. Novel mutations in the SH3BP2 gene associated with sporadic central giant cell lesions and cherubism.
Carvalho VM; Perdigão PF; Amaral FR; de Souza PE; De Marco L; Gomez RS
Oral Dis; 2009 Jan; 15(1):106-10. PubMed ID: 19017279
[TBL] [Abstract][Full Text] [Related]
40. Cherubism allele heterozygosity amplifies microbe-induced inflammatory responses in murine macrophages.
Prod'Homme V; Boyer L; Dubois N; Mallavialle A; Munro P; Mouska X; Coste I; Rottapel R; Tartare-Deckert S; Deckert M
J Clin Invest; 2015 Apr; 125(4):1396-400. PubMed ID: 25705883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
